ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?
ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
Alimera Sciences Reports Second Quarter 2024 Results
ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals
Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal
ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to Shareholders
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Alimera Sciences Reports First Quarter 2024 Results
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
New Strong Sell Stocks for March 13th
Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Alimera Appoints Maggie A. Pax to Its Board of Directors
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates
Alimera Sciences Reports Third Quarter 2023 Results
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
Alimera Sciences, Inc. (ALIM) Q2 2023 Earnings Call Transcript
Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates
Alimera Sciences Reports Second Quarter 2023 Results
Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update
Alimera Sciences (ALIM) Is Attractively Priced Despite Fast-paced Momentum
Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
Alimera (ALIM) Completes Enrollment in Eye Disease Study
Alimera Sciences (ALIM) Shows Fast-paced Momentum But Is Still a Bargain Stock
Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq
How to Develop a Penny Stocks Trading Mentality
Why Is Alimera Sciences (ALIM) Stock Up 21% Today?
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates
Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update
Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update